Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Beyond weight loss and all the associated benefits that come with that (such as less joint pain), these medications can treat metabolic diseases including type 2 diabetes, sleep apnea, fatty liver ...

As pharmaceutical companies intensify competition to capture a share of the fast-growing anti-obesity drug market, India’s drug regulator has cautioned firms against engaging in direct or indirect ...

By Dennis Thompson HealthDay ReporterTHURSDAY, March 12, 2026 (HealthDay News) — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the ...

While GLP-1 drugs can be effective for weight loss, they are not necessarily a permanent solution. Therefore, the duration of treatment can vary.

CDSCO issues advisory against promotional activities for anti-obesity, metabolic disorder drugs: Our Bureau, New Delhi Thursday, March 12, 2026, 12:45 Hrs [IST] The Central Drugs ...

(Yicai) March 12 -- US drugmaker Eli Lilly said it plans to invest USD3 billion to expand its supply chain capacity in China ...

India’s drug regulator CDSCO has asked pharmaceutical companies to stop promotional or awareness campaigns linked to GLP-1 ...

Weight loss injections like Wegovy can result in "very common" side effects ...

Recently, there has been a lot of news around the use of peptides in health circles. The US Department of Health and Human ...